RxDoctor Payments Data

Kauser Yasmeen, MD

Internal Medicine · Hicksville, NYNPI 1679519656

Payments from drug & device makers

$2,974in general payments, 2019–2025

Across 163 payments — averaging $18.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Sumitomo Pharma America, Inc.$279
  • Pfizer$277
  • Novo Nordisk$243
  • Boehringer Ingelheim$213
  • Lilly USA, LLC$132
  • plus $788 from 15 others

What the payments were for

  • Food & beverage$2,974100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,974 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$270,187
Medicare patients
448
Services billed
2,756

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate99$126,321
FarxigaDapagliflozin Propanediol123$125,948
EliquisApixaban178$103,208
OzempicSemaglutide57$88,928
JardianceEmpagliflozin56$72,172
JanumetSitagliptin Phos/Metformin Hcl54$48,756
XareltoRivaroxaban61$46,086
FycompaPerampanel22$44,705
TrulicityDulaglutide15$31,945
TradjentaLinagliptin50$30,189
MyrbetriqMirabegron34$23,516
MounjaroTirzepatide14$22,026
XcopriCenobamate19$14,486
Diclofenac Sodium58$13,771
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog66$13,764

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia, Janumet$129$175,077153 claims
AstraZenecaFarxiga$1,041$125,948123 claims
PfizerEliquis, Abrysvo$277$115,587212 claims
Boehringer IngelheimJardiance, Tradjenta$213$102,361106 claims
Novo NordiskOzempic$243$88,92857 claims
Lilly USA, LLCTrulicity, Mounjaro$132$53,97129 claims
Johnson & JohnsonXarelto$65$46,08661 claims
Astellas Pharma US IncMyrbetriq$12$23,51634 claims
NovartisEntresto$56$10,64718 claims
Sumitomo Pharma America, Inc.Gemtesa$279$8,61112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Hicksville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →